Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Cleveland-Cliffs Q4 2025 Earnings Call - Slab Contract Exit and POSCO MOU Prime 2026 for a Big EBITDA Bounce
Cleveland-Cliffs spent 2025 cleaning up self-inflicted and market-driven wounds, and management says 2026 will finally show the payoff. The company points to three structural moves as the inflection p...
- Q4 2025 shipments were 3.8 million tons, down seasonally from Q3; Q1 2026 shipments are expected to return to about 4.0 million tons.
- Full-year 2026 shipment guidance is 16.5 to 17.0 million tons as utilization ramps with improving demand.
- Q4 price realization was $993 per net ton, about $40/ton lower versus prior quarter; management expects realized prices to jump roughly $60/ton in Q1 2026.
- +12 more takeaways
Cleveland-Cliffs Q4 2025 Earnings Call - Slab Contract Exit and POSCO Talks Set Stage for a $500m EBITDA Lift in 2026
Cleveland-Cliffs framed 2025 as a fixing year and says 2026 is the payoff. Management pointed to three levers driving a materially better year: termination of the onerous ArcelorMittal slab contract, ...
- Cleveland-Cliffs terminated the index-based slab supply contract with ArcelorMittal; management pegs the full-year EBITDA uplift from replacing low-margin slabs with higher-margin product at roughly $500 million for 2026.
- Timing of slab benefit is phased, with sales already occurring in Q1 but the bulk of the profit flow expected to show up in Q2 and increase further through Q3 as inventory turns.
- Q4 2025 price realization was $993 per net ton, down about $40/ton versus Q3; management expects Q1 2026 realized price to be roughly $60/ton higher than Q4 and to continue grinding higher if current trends persist.
- +12 more takeaways
Inotiv Q1 FY2026 Earnings Call - DSA Growth Offsets NHP Weakness, Debt Refinancing Underway
Inotiv delivered a mixed Q1 FY2026. Total revenue inched up to $120.9 million, powered by a clear breakout in the drug discovery and safety assessment business, while the research models and services ...
- Total revenue was $120.9 million in Q1 FY2026, up 0.8% versus $119.9 million a year ago.
- DSA (Discovery and Safety Assessment) revenue rose 12% year-over-year to $48.0 million, driven by discovery pharmacology, surgical services, and strength at Rockville.
- Within DSA, discovery/translational sciences (DTS) grew 26% year-over-year, safety assessment revenue grew 7%.
- +16 more takeaways
Hain Celestial Fiscal Second Quarter 2026 Earnings Call - North America snacks sale to reduce debt and sharpen portfolio
Hain Celestial used Q2 as a turning point, announcing the sale of its North America snacks business to Snackrupters for $115 million in cash and laying out a multi-stage strategic review aimed at simp...
- Hain agreed to sell its North America snacks business to Snackrupters for $115 million in cash, expected to close in February, with proceeds earmarked to reduce debt.
- North America snacks represented 22% of company net sales in fiscal 2025 and 38% of North America segment sales, but produced negligible EBITDA over the last 12 months, and had become over-reliant on the club channel.
- Pro forma for the snacks divestiture, management expects leverage to fall from 4.9x at quarter end to roughly 4x, improving the company’s financial flexibility ahead of a December 2026 credit facility maturity.
- +17 more takeaways
Sally Beauty Holdings Q1 2026 Earnings Call - Margins, digital growth and cost cuts fuel an EPS beat despite flat comps
Sally Beauty delivered a cautious but solid start to fiscal 2026, beating on EPS and showing healthy margin expansion while top-line growth remains tepid. Consolidated sales of $943 million were essen...
- Consolidated net sales of $943 million, up 0.6% year over year, with comparable sales essentially flat versus prior year.
- Adjusted diluted EPS was $0.48, up 12% year over year, and came in above guidance.
- Adjusted gross margin expanded 50 basis points to 51.3%, driven primarily by higher product margins from the Fuel for Growth program.
- +16 more takeaways
Kyndryl Q3 FY2026 Earnings Call - Longer sales cycles and evolving IBM content trim near-term revenue despite margin and cash momentum
Kyndryl reported Q3 results with revenue of $3.9 billion, flat in constant currency, and signings of $3.9 billion for the quarter. The company delivered margin expansion, higher adjusted pre-tax incom...
- Leadership update, Harsh Chugh named Interim CFO and joined the call to walk through the quarter.
- Q3 revenue was $3.9 billion, up 3% reported and flat in constant currency.
- Q3 signings were $3.9 billion, with 11 contracts over $50 million and $15.4 billion in last‑12‑month signings, keeping trailing 12‑month book‑to‑bill above 1.0.
- +12 more takeaways
Edgewell Q1 FY2026 Earnings Call - FemCare Exit Sharpens Focus, Productivity and International Growth to Drive Recovery
Edgewell closed the divestiture of its FemCare business on February 2, 2026, and the company says the sale improves the underlying margin profile and simplifies capital allocation. Q1 results were mod...
- FemCare sale closed on February 2, 2026, and management calls the divestiture a net positive for underlying margins and strategic focus.
- Edgewell recast prior periods and now presents results and outlook on continuing operations, excluding FemCare.
- Q1 continuing operations: organic net sales down 50 basis points, consolidated organic net sales down 30 basis points, modestly ahead of company expectations.
- +12 more takeaways
Anavex Life Sciences Q1 2026 Earnings Call - Blarcamesine heads into EMA re-examination after CHMP negative opinion, FDA Type C feedback and ACCESS-AD tie‑in
Anavex used the quarter to double down on oral blarcamesine for early Alzheimer’s disease while navigating a bruising regulatory landscape. The European Medicines Agency issued a negative CHMP opinion...
- CHMP issued a negative opinion on the marketing authorization application for blarcamesine in December; Anavex formally requested EMA re-examination under different rapporteur and co-rapporteur.
- Company expects the EMA re-examination process to follow a 60 plus 60 day cadence and to unfold in the first half of the year, but outcome is not guaranteed.
- Anavex held a Type C meeting with the FDA; the company plans to submit the full Phase IIb/III Anavex 2-73-AD-004 data package to the agency as the next regulatory step.
- +10 more takeaways
Sohu Q4 2025 Earnings Call - $285M Changyou Tax Reversal Masks Weak Ad Business
Sohu reported a quarter propped up by a one-time $285 million reversal of accrued withholding tax related to Changyou, which flipped GAAP earnings from last year’s loss to a $223 million net income. U...
- Sohu total revenue for Q4 2025 was $142 million, up 6% year-over-year and down 21% sequentially.
- Management disclosed a reversal of previously accrued withholding income tax of approximately $285 million related to Changyou, a one-time item that materially boosted GAAP results.
- After the tax reversal GAAP net income attributable to Sohu was $223 million in Q4 2025, versus a net loss of $21 million in Q4 2024.
- +13 more takeaways
Curbline Properties Q4 2025 Earnings Call - 12% FFO Growth Targeted in 2026 Backed by $700M Investment Plan and Strong Liquidity
Curbline closed its first full year as a public company by underscoring a fast-growth, capital-efficient play in the convenience retail niche. Management reported outsized operational performance in Q...
- Curbline acquired just under $800 million of assets in 2025, driven by both one-off deals and portfolio transactions.
- Management signed over 400,000 sq ft of new leases and renewals in 2025, with new lease spreads averaging 20% and renewal spreads just under 10%.
- Same-property NOI grew 3.3% for the full year 2025 and 1.5% in Q4, despite a roughly 50 basis point headwind from uncollectible revenue in the quarter.
- +16 more takeaways